Fyarro is given as an intravenous (IV) infusion, meaning it is slowly dripped into a vein, usually in your arm, by a healthcare professional in a hospital or clinic. It is typically administered on Days 1 and 8 of each 21-day cycle. Each infusion usually takes about 30 minutes.

• Administration: Given by IV infusion by a healthcare professional.
• Schedule: Administered on Days 1 and 8 of a 21-day cycle.
• Infusion Time: Each infusion takes approximately 30 minutes.
• Treatment Duration: Treatment continues until your cancer worsens or you experience side effects that are too severe to manage.
• Monitoring: You will be closely monitored during and after each infusion for any reactions.

It’s vital to attend all your scheduled appointments for infusions and follow-up monitoring as directed by your doctor.

Fyarro works by targeting a specific protein pathway inside cells called the mTOR (mechanistic Target of Rapamycin) pathway. In many cancer cells, especially in malignant PEComa, this mTOR pathway is overactive or “stuck on,” constantly sending signals that tell the cancer cells to grow, divide, and survive. Fyarro acts as an mTOR inhibitor, meaning it blocks or “turns off” this overactive signaling pathway. By shutting down the mTOR signals, Fyarro helps to stop the uncontrolled growth and division of the cancer cells. The special albumin-bound particle formulation of sirolimus in Fyarro is designed to help deliver higher amounts of the drug directly into the tumor, improving its ability to block these growth signals and slow down or stop the tumor’s progression.

• Fyarro targets the mTOR pathway in cancer cells.
• In PEComa, the mTOR pathway is often overactive, causing cell growth.
• Fyarro blocks these “grow” signals by inhibiting mTOR.
• This action stops the uncontrolled growth and division of cancer cells.
• Nanoparticle technology helps deliver more drug to tumors.

Like all cancer treatments, Fyarro can cause side effects. Your doctor will monitor you closely and manage these. Common side effects include:

• Mouth ulcers or sores (stomatitis): Very common and can be severe.
• Fatigue or weakness.
• Rash.
• Infections: Can increase your risk of infections.
• Nausea, vomiting, diarrhea, constipation.
• Swelling (edema): Of hands, feet, face, or other body parts.
• Muscle and joint pain, back pain.
• Decreased appetite and weight loss.
• Cough.
• Changes in taste.
• Blood count changes: Decreased white blood cells, red blood cells (anemia), and platelets.
• Electrolyte imbalances: Low potassium (hypokalemia), high blood sugar (hyperglycemia).
• Lung inflammation (pneumonitis): Can cause persistent cough, chest pain, shortness of breath.
• Bleeding: Serious bleeding, even fatal, can occur.

Report any new or worsening symptoms to your healthcare team immediately

Fyarro is a powerful cancer drug, and several important warnings and precautions are associated with its use:

• Mouth Sores (Stomatitis): Be vigilant for pain or sores in your mouth; report them promptly.
• Infections: Increased risk of serious infections. Report fever, chills, or feeling unwell.
• Lung Problems (Pneumonitis): Monitor for new or worsening cough, chest pain, or difficulty breathing.
• Bleeding: Serious and potentially fatal bleeding can occur. Watch for any signs of unusual bleeding.
• Hypersensitivity Reactions: Allergic reactions, including severe ones, can happen. Monitor during and after infusion.
• Embryo-Fetal Toxicity: Can harm an unborn baby. Women of childbearing potential must use effective contraception during treatment and for 12 weeks after the last dose. Men with female partners must also use contraception.
• Fertility: May impair fertility in both males and females.
• Immunizations: Avoid live vaccines during treatment.

Fyarro can have significant interactions with other medicines because it is processed by certain enzymes in the liver. It’s crucial to inform your doctor about all medications, supplements, and herbal products you are taking. Key interactions include:

• Strong CYP3A4 and/or P-gp Inhibitors/Inducers: Medicines that strongly block or speed up the work of certain liver enzymes (CYP3A4) or transporters (P-gp) can greatly change the amount of Fyarro in your body.
  • Inhibitors (e.g., some antifungals like ketoconazole, some antibiotics like clarithromycin, certain HIV medicines) can increase Fyarro levels, leading to more side effects.
  • Inducers (e.g., some anti-seizure drugs, rifampin) can decrease Fyarro levels, making it less effective.
• Grapefruit and Grapefruit Juice: These products can also increase Fyarro levels and should be avoided during treatment.
• Live Vaccines: You should not receive live vaccines during treatment with Fyarro, as your immune system may be weakened.

Your oncology team will carefully review your medication list and may adjust doses or recommend avoiding certain drugs to manage these interactions safely.

The recommended dosage of Fyarro for adult patients is 100 mg per square meter (mg/m²) of body surface area. This dose is given as an intravenous (IV) infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.

• Standard Dose: 100 mg/m² per infusion.
• Schedule: Administered on Day 1 and Day 8 of a 21-day cycle.
• Infusion Duration: Each infusion takes 30 minutes.
• Duration of Therapy: Treatment continues until the disease progresses (worsens) or until side effects become too severe to manage.
• Dose Adjustments: Your doctor may reduce the dose (e.g., to 75 mg/m² or 56 mg/m²) or temporarily stop treatment if you experience certain serious side effects.
• Monitoring: Regular blood tests (including blood counts, liver/kidney function, electrolytes, and blood sugar) will be performed before and during treatment to guide dosing and manage side effects.

Strict adherence to the prescribed dosage and schedule is crucial for effectiveness and safety.

Fyarro is a prescription-only medication (POM). It is a highly specialized and potent cancer drug, and therefore, it cannot be purchased without a valid prescription from a licensed medical doctor, specifically an oncologist. Its use is limited to adult patients with a confirmed diagnosis of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). Due to the complex nature of cancer therapy, the need for precise dosage calculations (based on body surface area), intravenous administration, and extensive monitoring for severe side effects, Fyarro is administered and managed by experienced oncology teams, typically within a hospital or specialized cancer treatment center.

• Fyarro is a prescription-only medication (POM).
• Requires a valid prescription from a licensed medical oncologist.
• Not available over-the-counter.
• Used for a specific, rare cancer (PEComa).
• Administered and managed by oncology teams in specialized settings due to complexity and need for close monitoring.

What is Fyarro used for? Treatment of locally advanced unresectable or metastatic perivascular epithelioid cell tumors (PEComa) in adults

2. What is the active ingredient? Sirolimus protein-bound particles (albumin-bound)

3. What drug class does it belong to? mTOR inhibitor (targeted anticancer therapy)

4. Is Fyarro a controlled substance? No

5. Is Fyarro available in generic form? No

6. How is Fyarro administered? Intravenous infusion

7. What strengths are available? 100 mg vial for reconstitution

8. What is the usual adult dosage? Once weekly IV infusion at 100 mg/m² until disease progression or unacceptable toxicity

9. Can it be used in children? Not approved for pediatric use

10. What are common side effects? Stomatitis, rash, fatigue, nausea, diarrhea, anemia

11. Can it cause serious reactions? Yes—severe infections, pneumonitis, hypersensitivity, renal/hepatic dysfunction

12. Is Fyarro safe during pregnancy? No—can cause fetal harm; contraindicated in pregnancy

13. Is a prescription required? Yes

14. Is Fyarro available in Pakistan? Not widely; may be accessed via oncology specialty import programs

15. How should it be stored? Refrigerated at 2–8°C; protect from light; do not freeze

16. What precautions should be taken during use? Monitor blood counts, renal and hepatic function, and signs of infection

17. What are contraindications? Hypersensitivity to sirolimus or albumin-bound formulations

18. What monitoring is needed during use? CBC, renal and liver function tests, lipid profile, infection surveillance

19. Can Fyarro be combined with other anticancer drugs? Yes—may be used in combination regimens, but requires careful monitoring for toxicity

20. What are similar drugs? Other mTOR inhibitors: everolimus (Afinitor), temsirolimus (Torisel), sirolimus (Rapamune – immunosuppressant use)